REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 16th, 2013 • AmpliPhi Biosciences Corp • Biological products, (no disgnostic substances)
This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 16, 2013, by and among AmpliPhi Biosciences Corporation, a Washington corporation (the “Company”), and the several purchasers signatory hereto (each a “Purchaser” and collectively, the “Purchasers”).
EMPLOYMENT AGREEMENTEmployment Agreement • December 16th, 2013 • AmpliPhi Biosciences Corp • Biological products, (no disgnostic substances) • Virginia
THIS AGREEMENT (the “Agreement”) is made and entered into effective as of October 19, 2011 by and between AmpliPhi Biosciences Corporation, a Delaware corporation, having an address of 601 Union Street, Suite 4200, Seattle, WA 98101 (the “Company”), and Mr. Philip J. Young (the “Executive”).
Exclusive Channel Collaboration AgreementExclusive Channel Collaboration Agreement • December 16th, 2013 • AmpliPhi Biosciences Corp • Biological products, (no disgnostic substances) • New York
This Exclusive Channel Collaboration Agreement (the “Agreement”) is made and entered into effective as of March 29, 2013 (the “Effective Date”) by and between Intrexon Corporation, a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and Ampliphi Biosciences Corporation, a Washington corporation having a place of business at 800 E. Leigh St., Suite 54, Richmond, VA, 23219 (“Ampliphi”). Intrexon and Ampliphi may be referred to herein individually as a “Party”, and collectively as the “Parties.”
ContractCollaboration Agreement • December 16th, 2013 • AmpliPhi Biosciences Corp • Biological products, (no disgnostic substances) • England and Wales
Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.
VIRGINIA BIOTECHNOLOGY CENTER VIRGINIA BIOTECHNOLOGY RESEARCH PARK AGREEMENT OF LEASELease Agreement • December 16th, 2013 • AmpliPhi Biosciences Corp • Biological products, (no disgnostic substances) • Virginia
THIS AGREEMENT OF LEASE, dated as of the 23rd day of February, 2011 by and between VIRGINIA BIOTECHNOLOGY RESEARCH PARTNERSHIP AUTHORITY, a political subdivision of the Commonwealth of Virginia created by an act of the Virginia General Assembly, the purpose of which is to develop and operate the Virginia Biotechnology Research Park for the purpose of expanding, developing and commercializing knowledge pertaining to scientific and technological research among public and private entities including, but not limited to, knowledge in the area of the biotechnology and biomedical sciences (the "Authority"), and AMPLIPHI BIOSCIENCES CORPORATION, a Washington Corporation, (the "Tenant"), recites and provides:
Client Services Agreement Pacific Business CentersClient Services Agreement • December 16th, 2013 • AmpliPhi Biosciences Corp • Biological products, (no disgnostic substances) • California
SUBSCRIPTION AGREEMENTSubscription Agreement • December 16th, 2013 • AmpliPhi Biosciences Corp • Biological products, (no disgnostic substances) • New York
SUBSCRIPTION AGREEMENTSubscription Agreement • December 16th, 2013 • AmpliPhi Biosciences Corp • Biological products, (no disgnostic substances) • New York
ContractCooperative Research and Development Agreement • December 16th, 2013 • AmpliPhi Biosciences Corp • Biological products, (no disgnostic substances)
Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.
ContractCollaboration Agreement • December 16th, 2013 • AmpliPhi Biosciences Corp • Biological products, (no disgnostic substances) • England and Wales
Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.
Dated 8 December 2011 LEASE Between and of Rooms 11, 12,15, 16,18,18A, 18B, 130, 130A and 130B Colworth House Annex, Colworth Science Park, Sharnbrook, Bedfordshire Particulars ConditionsLease • December 16th, 2013 • AmpliPhi Biosciences Corp • Biological products, (no disgnostic substances)
In this lease all defined terms shall adopt the definitions given to them on the page entitled "Particulars", and ‘we’, ‘us’, and ‘our’ shall mean the Landlord named in the Particulars ‘you’ and ‘your’ shall mean the Tenant named in the Particulars.
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENTEmployment Agreement • December 16th, 2013 • AmpliPhi Biosciences Corp • Biological products, (no disgnostic substances)
This Amendment No. 1 to Employment Agreement (the “Amendment”) is entered into as of June 25, 2013 by and between AmpliPhi Biosciences Corporation, a Washington corporation (the “Company”) and Mr. Philip J. Young (the “Executive”).
STOCK ISSUANCE AGREEMENTStock Issuance Agreement • December 16th, 2013 • AmpliPhi Biosciences Corp • Biological products, (no disgnostic substances) • New York
This Agreement (“Agreement”) is made and entered into as of March 29, 2013 (the “Effective Date”), by and among AmpliPhi Biosciences Corporation, a Washington corporation (the “Company”), and Intrexon Corporation, a Virginia corporation (“Intrexon”).
